Limitations of Conventional Imaging for Assessing Renal Masses

Experts on kidney cancer review challenges associated with limitations of conventional imaging for assessing renal masses and how to potentially improve sensitivity and specificity.

EP: 1.A Growing Incidence of Renal Masses

EP: 2.Diagnostic Tests for Kidney Cancer

Now Viewing

EP: 3.Limitations of Conventional Imaging for Assessing Renal Masses

EP: 4.The Role of a Multidisciplinary Team in Managing Kidney Cancer

EP: 5.Staging and Treatment Decisions for Kidney Cancer

EP: 6.Advances in Imaging for Kidney Cancer Diagnosis and Management

EP: 7.Overview of Clinical Trials for New Imaging Options for Kidney Cancer

EP: 8.Potential Impact of PET/CT Imaging on Improving Patient Care

Related Videos

Related Content

Advertisement

January 2nd 2025

Cellular structures show link with survival outcomes in ccRCC

Hannah Clarke

Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

December 19th 2024

First patient dosed in phase 1 trial of ADI-270 in ccRCC

Hannah Clarke

Initial data from the trial are expected to be released in the first half of 2025.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke

Initial results on ADI-270 are anticipated for the first half of 2025.

November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke

Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.

Related Content

Advertisement

January 2nd 2025

Cellular structures show link with survival outcomes in ccRCC

Hannah Clarke

Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

December 19th 2024

First patient dosed in phase 1 trial of ADI-270 in ccRCC

Hannah Clarke

Initial data from the trial are expected to be released in the first half of 2025.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke

Initial results on ADI-270 are anticipated for the first half of 2025.

November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke

Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.